已收盤 10-17 16:00:00 美东时间
-0.740
-1.79%
Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025.
10-14 00:46
Cramer praises Arista Networks' performance and Needham analyst's positive outlook. Applied Digital loses money, Cramer prefers Costco over Sprouts.
10-01 20:16
今日重点评级关注:Maxim Group:维持T Stamp"买入"评级,目标价从8美元升至12美元;Maxim Group:维持Rezolute"买入"评级,目标价从15美元升至20美元
09-22 18:44
Oppenheimer analyst Ian Zaffino maintains Resideo Technologies (NYSE:REZI) with a Outperform and raises the price target from $35 to $48.
09-19 21:12
"Mad Money" star Jim Cramer discusses MP Materials, Resideo Technologies and Canadian National Railway on Friday, Sept. 12.
09-12 19:58
Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the REZILIENT1 and REZILIENT2 trials of zipalertinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic
09-09 17:49
Magic Software has extended its rally after a major breakout, with bullish momentum intact. Here's what could be next for the stock.
08-14 20:03
Resideo Technologies (NYSE: REZI) has broken out of its Adhishthana Cakra in Phase 9, signaling strong bullish potential with a rally likely to continue into Phase 10.
08-13 23:59
Resideo Technologies (REZI) ended Honeywell indemnification with $1.59B buyout, leading to cleaner earnings, upgraded price forecast of $35 by Morgan Stanley.
08-13 02:07
Resideo Technologies (NYSE:REZI) jumped over 14% during early trading hours on Tuesday as Morgan Stanley upgraded the stock to Overweight from Equaweight. The brokerage firm increased its price targe...
08-12 22:24